The spine surgeon in the Center for Spine Health at Cleveland Clinic discussed the importance of patient-reported outcomes for patients who are undergoing spine surgery.
A study comparing 2 doses of minocycline falls short as the drug failed to slow progression of cognitive or functional decline in people with AD.
The director of the Epilepsy Center and vice chair of the Neurological Institute for Strategy and Development at Cleveland Clinic discussed the advanced application of telemedicine at Cleveland Clinic.
An analysis of ACHIEVE II suggests that the oral CGRP antagonist from Allergan provides significant pain freedom and relief of the most bothersome symptoms for adults with migraine for at least one dose assessed.
The spine surgeon in the Center for Spine Health at Cleveland Clinic spoke about the improvements in minimally invasive surgery and the areas ripe for innovation.
The neurologist at the Huntington’s Disease Center at University College London spoke about the clinical development of RG6042 in the treatment of Huntington disease, and what to expect from the GENERATION HD1 study.
A lower target for low-density lipoprotein is associated with a greater reduction in cardiovascular events after ischemic stroke over a higher LDL target.
SK Life Science’s investigational agent cenobamate has shown an ability to significantly reduce focal-onset seizures in doses of 100, 200, and 400-mg compared to placebo. An NDA was filed for the therapy in early 2019.
The director of the Epilepsy Center at Cleveland Clinic reviewed the role that wearable technology can play in detecting seizures in patients with epilepsy.
Benjamin Walter, MD, medical director of the Deep Brain Stimulation Program at Cleveland Clinic shared his personal experience with deep brain stimulation and focused ultrasound and the potential of the procedures.
Neurology News Network for the week ending November 16, 2019.
Data from a new study demonstrates valbenazine’s ability to effectively reduce TD symptoms over a long-term period.
The director of the Epilepsy Center at Cleveland Clinic discussed why cannabidiol should be used cautiously in patients with epilepsy.
The medical director of the Deep Brain Stimulation Program at Cleveland Clinic discussed how the medical field is beginning to explore the full range of focused ultrasound’s capabilities to aid treatment in Parkinson disease.
Pooled analysis from 3 studies of more than 1000 patients with migraine suggest that galcanezumab (Emgality, Eli Lilly) has good cardiovascular safety and is not linked with vasoconstriction or an increase in cardiovascular adverse events.
An automated deep neural network, SpikeNet, performed at or above the accuracy, sensitivity, and specificity of fellowship-trained clinical experts in identifying interictal epileptiform discharges.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Amaal Starling, MD.
The chief of cerebrovascular disease at Jefferson University Hospitals detailed the importance and growth of mobile stroke units.
Alireza Atri, MD, PhD, medical director of the Banner Sun Health Research Institute, spoke about the importance of open-ended cognitive screening, and the value that early detection and intervention can bring to the table.
Interictal epileptiform discharges on EEG readings had a positive predictive value of 77.3% and a negative predictive value of 70 %, with a sensitivity of detecting spikes prior to epilepsy of 85%.
The medical director of the Deep Brain Stimulation Program at Cleveland Clinic spoke to the need for physicians to inform patients with movement disorders of DBS and the options that they may have for treatment.
The director of the Epilepsy Center at Cleveland Clinic explained why epilepsy surgery should be recommended and incorporated more.
Patients in small-scale trial experienced a drastic reduction in monthly headache days after just 1 dose of erenumab.
The chief of cerebrovascular disease at Jefferson University Hospitals explains why teaching stroke protocol and using telemedicine can help close the gaps in stroke care.
This is the third safety incident in the IGNITE DMD clinical trial that has resulted in a clinical hold since its inception in 2017.
The director of Centers for Neuropsychology and Neuroscience Research and Traumatic Brain Injury Research at Kessler Foundation spoke to the use of strategy training and how it mirrors real-life situations for patients with MS and TBI.
The medical director of the Deep Brain Stimulation Program at Cleveland Clinic shared his perspective on deep brain stimulation and its impact on the treatment landscape.
An 8 year old boy with genetically confirmed neurofibromatosis type 1 presents with first generalized seizure.
Patients with spinal muscular atrophy types 2 or 3 saw improvements in motor function after receiving risdiplam; data will be presented at an upcoming medical congress.
The director of the Epilepsy Center and vice chair of Neurological Institute for Strategy and Development at Cleveland Clinic detailed how researchers are working to utilize a biomarker to enhance epilepsy surgery.
